Unknown

Dataset Information

0

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).

ABSTRACT: Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.

SUBMITTER: Lee EK 

PROVIDER: S-EPMC7021536 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).

Lee Elizabeth K EK   Tan-Wasielewski Zhenying Z   Aghajanian Carol C   Coleman Robert L RL   Curtis Jennifer J   Hirsch Michelle S MS   Matulonis Ursula A UA   Cantley Lewis C LC   Mills Gordon B GB   Doyle L Austin LA   Liu Joyce F JF  

Gynecologic oncology reports 20200203

Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AK  ...[more]

Similar Datasets

Unknown Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.
| S-EPMC3088633 | biostudies-literature
Unknown High grade serous ovarian carcinomas originate in the fallopian tube.
| S-EPMC5653668 | biostudies-literature
Unknown YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.
| S-EPMC4791205 | biostudies-literature
Unknown High-grade serous ovarian cancer arises from fallopian tube in a mouse model.
| S-EPMC3309733 | biostudies-literature
Unknown PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
| S-EPMC5581540 | biostudies-literature
Unknown Reconstitution of high-grade serous ovarian carcinoma from primary fallopian tube secretory epithelial cells.
| S-EPMC5849158 | biostudies-literature
Unknown Peritoneal Dialysis Catheter-Fallopian Tube Fistula.
| S-EPMC7403557 | biostudies-literature
Unknown Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
| S-EPMC4383665 | biostudies-literature
Unknown Fallopian tube single cell analysis reveals myeloid cell alterations in high-grade serous ovarian cancer.
| S-EPMC10879678 | biostudies-literature
Unknown Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma.
| S-EPMC3043379 | biostudies-literature